APDN update from Annual Shareholder’s Meeting


 I attended the annual shareholder’s meeting today and wanted to provide an update. I’ll first give an overview, and then dig down into each vertical. Overview The meeting was comprehensive and well put together. All directors attended except for one and every member of the executive team was there along with some lower level employees. There were stations setup with More »

ACUR – Q4 2015 Conference Call Thoughts


 As a follow up to my original note on ACUR, I just wanted to add some thoughts from the ACUR Q4 2015  conference call, located here  “Dosing in the first cohort of AP-LTX-400 commenced in late February 2016, and the entire cohort is enrolled.”  Enrollment is not an issue – that is positive. “We expect study LTX-400 to complete enrollment, More »

Low-float Acura, Back from the dead, finds itself in the FDA sweet spot


 On February 2nd, 2016, President Obama released a statement that he would ask Congress for $1.1 Billion to fight the opioid epidemic, which includes both heroin and abuse of prescription opiates. White House Press Release asking for funding for opiate abuse Coincidentally, this was released the morning after Acura Pharmaceuticals announced they were allowed to resume clinical testing of its abuse-deterrent More »

APDN Revenue up 7% YoY


 My quick thoughts on today’s results and conference call. I managed to ask two questions on the call… — SUMMARY and My Conclusions… 1. Revenue was in-line with my Q1 estimate 2. Company re-affirmed > $3.6M cotton revenue and > $9.0M company revenue for the year 3. Growth focus beyond cotton this year will be DNANet, Polyester, and Polyolefins. It’s More »

APDN up 27% as it Reports Record Q4 Revenue of $4M, a 517% increase over Q4 2014, and 75% Sequential Increase over Q3


 APDN filed their 10-K tonight for fiscal year 2015 ending September 30th and they reported $4M in revenue for Q4 and $9M in revenue for the year. For the quarter, APDN beat analyst estimates by 100%. Q4 revenue was a 517% increase over Q4 2014. FY revenue of $9M was a 230% increase over 2014. Additionally, APDN reported an adjusted More »

APDN Poised to Report 200% – 440% Revenue Increase Tonight. $5 – $7 Near-term Upside and $15 12-month Target.


 This is a quick earnings preview on APDN. For full coverage see the other APDN articles on the site. APDN is set to report earnings for it’s Fiscal Q4 and FY 2015 after the close today. APDN will file a 10-K after the close. They typically file around 5pm EST. This will be followed by a PR between 5am and More »

CORRECTION: CEO Suggests APDN will be Profitable in Quarter Ending September, NOT December!


 This is an important correction to a story published on StoryTrading on November 19th, titled “APDN up 10% as Short Perpetrator Reported to Authorities & CEO Suggests Company will be Profitable in Quarter Ending December 31st.” Below you’ll see why this title should have read “September 30th” at the end. Upon carefully re-reviewing the webcast, it appears that Dr. Hayward, CEO More »

November 12th E-mail from Patrick Cox Explains how APDN was able to get “PumpStopper” to go on the Run


 Check out the below email from Patrick Cox written on November 12th. After you read this, you will understand how APDN was able to get the PumpStopper to go on the run by shutting down his website and his Twitter. Soon we may see the SA hit piece removed as well. * the source for the below email is a More »

APDN up 10% as Short Perpetrator Reported to Authorities & CEO Suggests Company will be Profitable in Quarter Ending December 31st


 This is a fast-breaking and developing update to our refutation of the APDN short piece written on SeekingAlphha. There are 3 catalysts TODAY causing the stock to pop: This morning, APDN issued a press release reporting that they have identified the short author of the SA article along with his co-conspirator. Both have been reported to the Fed and the More »

APDN Revenue Set to Surge 480% as Shorts Fabricate False Story Line Ahead Of Record Results.


 Disclosures: I am long APDN. I wrote this article myself and it represents my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. Summary Short article by “The Pump Stopper” created false story line about the “hype” of Patronus deal and published false information about More »